NARCX | NWXUX | NARCX / NWXUX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 30 years | 8 years | - |
Gain YTD | 2.690 | 1.329 | 202% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 1000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 291M | 284M | 102% |
Annual Yield % from dividends | 1.16 | 2.37 | 49% |
Returns for 1 year | 9.87 | 6.43 | 153% |
Returns for 3 years | 4.37 | -3.23 | -135% |
Returns for 5 years | 14.82 | 6.68 | 222% |
Returns for 10 years | 39.96 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
EAFGX | 28.16 | 0.49 | +1.77% |
Eaton Vance Focused Growth Opps A | |||
EEMHX | 8.02 | 0.02 | +0.25% |
MFS Emerging Markets Equity Research R6 | |||
JFNCX | 58.22 | 0.01 | +0.02% |
Janus Henderson Global Life Sciences C | |||
VWYGX | 44.71 | N/A | N/A |
Voya Small Cap Growth C | |||
WOOPX | 19.12 | -0.10 | -0.52% |
JPMorgan SMID Cap Equity I |